FleischmannRM. Is there a need for new therapies for rheumatoid arthritis?J Rheumatol2005;73:3–7; discussion 29–30.
2.
GodfreyC.In the beginning. J Rheumatol2000;27:1599–600.
3.
KayEA. The changing role of the clinical pharmacist in rheumatology. Br J Rheumatol1986;25:87–90.
4.
PincockS.The quest for pain relief: how much have we improved on the past?The Scientist2005;19(suppl 1):S31.
5.
DayRO. Variability in response to NSAIDs: what progress?Agents Actions Suppl1993;44:3–6.
6.
Garcia RodriguezLA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med1998;104(suppl 3A):30S-4S; discussion 41S-2S.
7.
Methotrexate in rheumatoid arthritis. Health and Public Policy Committee, American College of Physicians. Ann Intern Med1987;107:418–9.
8.
CallahanLF, LappinDR. The Arthritis Foundation 1948–1998: 50 years of arthritis care and research. Arthritis Care Res1998;11:309–14.
9.
O'DellJR, LeffR, PaulsenG, . Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum2002;46:1164–70.
10.
Goldbach-ManskyR, LipskyPE. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med2003;54:197–216.
11.
Resman-TargoffBH. Medical therapy: where are we now?Am J Health Syst Pharm2006;63(suppl 4):S11–8.
12.
PucinoFJr, HarbusPT, Goldbach-ManskyR.Use of biologics in rheumatoid arthritis: where are we going?Am J Health Syst Pharm2006;63(suppl 4):S19–41.
13.
ReindersMK, Van RoonEN, BrouwersJR, JansenTL. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable (letter)?Ann Rheum Dis2005;64:516; author reply 516.
14.
RichetteP, BardinT.Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Natl Clin Pract Rheumatol2006;2:338–42.
15.
ViktilKK, BlixHS, MogerTA, ReikvamA.Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRPs). Pharmacoepidemiol Drug Saf2006;15:667–74.
16.
CooperJW, WadeWE. Pharmacist interventions in geriatric nursing facility NSAID therapy: a one-year follow-up study of costs and outcomes. Consult Pharm2005;20:492–7.
17.
ChenJT, PucinoF, Resman-TargoffBH. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?J Pain Pall Care Pharmacother2006;20(4):11–32.
18.
ErnstME, DoucetteWR, DedhiyaSD, . Use of point-of-service health status assessments by community pharmacists to identify and resolve drug-related problems in patients with musculoskeletal disorders. Pharmacotherapy2001;21:988–97.
19.
OsterhausJT, DedhiyaSD, ErnstME, OsterhausM, MehtaSS, TownsendRJ. Health outcomes assessment in community pharmacy practices: a feasibility project. Arthritis Rheum2002;47:124–31.
20.
MarraCA, CibereJ, TsuyukiRT, . Improving osteoarthritis detection in the community: the pharmacist identification of new, diagnostically confirmed osteoarthritis (PhIND -OA) study. Arthritis Care Res2007 (in press).
21.
HayEM, FosterNE, ThomasE, . Effectiveness of community physiotherapy and enhanced pharmacy review for knee pain in people aged over 55 presenting to primary care: pragmatic randomized trial. BMJ2006;333:995–8.
